The Advantages of Kinome Profiling With a Continuous Assay
Learn how a continuous assay format can provide you with more kinetic observations for deeper insights into your compound.
Webinar Overview:
A key component of drug discovery is the evaluation of compound selectivity. Profiling against a broad selection of kinases is conducted with a variety of assay formats and almost all of these are endpoint assays which rely on a single time point with the assumption that the signal at that time is a good estimate of the initial reaction rate.
A continuous assay format offers distinct advantages over the endpoint format because it captures the true reaction rate directly from the slope of the progress curve with many time points, yielding much higher confidence in this critical parameter. With these additional kinetic observations, you can get deeper insight into the compound mode of action.
Join our webinar to learn how our PhosphoSens® continuous assays provide advantages in kinome profiling.
You’ll learn:
- The differences between an endpoint and continuous assay for kinome profiling
- Kinetic insights that lie behind the raw data
- Examples of interesting progress curves and how you can use them to identify aspects of an inhibitor’s mode of action
Meet Your Presenter:
Earl May, Ph.D., Senior Director of Discovery Technologies
Earl has 25+ years of expertise in drug discovery and enzymology from GSK, OSI and several other biotechnology companies. He has used our Sox sensor peptide technology at all companies he had kinase inhibitor programs, with both reversible and covalent compounds.
